share_log

康寧傑瑞製藥-B：自願公告 - 於2024年AACR年會呈列的JSKN003用於治療HER2表達晚期實體瘤的I期臨床研究的最新結果

ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - UPDATES ON RESULTS OF A PHASE I CLINICAL TRIAL OF JSKN003 FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED SOLID TUMORS FOR PRESENTATION AT 2024 AACR ANNUAL MEETING

香港交易所 ·  Apr 9 18:05
Summary by Moomoo AI
康寧傑瑞生物製藥（ALPHAMAB ONCOLOGY）於2024年4月5日至10日的美國癌症研究協會年會（AACR）上，發表了其藥物JSKN003用於治療HER2表達晚期實體瘤的I期臨床研究最新結果。該研究顯示，JSKN003在晚期╱轉移性實體瘤患者中具有良好的耐受性和安全性，並展現出初步的抗腫瘤活性。研究結果包括32例患者的數據，其中多數患者接受過至少三線系統性治療。療效方面，客觀緩解率（ORR）和疾病控制率（DCR）分別為56.3%和90.6%。藥物的血液毒性和間質性肺疾病（ILD）的發生率低。JSKN003是一種靶向HER2的抗體偶聯藥物（ADC），目前在澳大利亞和中國進行臨床試驗，並推進中國III期臨床試驗。康寧傑瑞生物製藥是一家專注於腫瘤治療的生物製藥公司，擁有多個處於不同研發階段的產品。
康寧傑瑞生物製藥（ALPHAMAB ONCOLOGY）於2024年4月5日至10日的美國癌症研究協會年會（AACR）上，發表了其藥物JSKN003用於治療HER2表達晚期實體瘤的I期臨床研究最新結果。該研究顯示，JSKN003在晚期╱轉移性實體瘤患者中具有良好的耐受性和安全性，並展現出初步的抗腫瘤活性。研究結果包括32例患者的數據，其中多數患者接受過至少三線系統性治療。療效方面，客觀緩解率（ORR）和疾病控制率（DCR）分別為56.3%和90.6%。藥物的血液毒性和間質性肺疾病（ILD）的發生率低。JSKN003是一種靶向HER2的抗體偶聯藥物（ADC），目前在澳大利亞和中國進行臨床試驗，並推進中國III期臨床試驗。康寧傑瑞生物製藥是一家專注於腫瘤治療的生物製藥公司，擁有多個處於不同研發階段的產品。
CORNING JERRY BIOPHARMACEUTICALS (ALPHAMAB ONCOLOGY) ANNOUNCED THE LATEST RESULTS OF A PHASE I CLINICAL TRIAL OF ITS DRUG JSKN003 FOR THE TREATMENT OF HER2-EXPRESSED LATE-STAGE SOLID TUMORS ON APRIL 5-10, 2024. The study showed that JSKN003 had good tolerability and safety in patients with late-stage and metastatic solid tumors, and showed initial antitumor activity. The results include data from 32 patients, most of whom received at least three-line systemic therapy. In terms of efficacy, the objective mitigation rate (ORR) and disease control rate (DCR) are 56.3% and 90.6%, respectively. The drug has a low rate of hematotoxicity and interstitial lung disease (ILD). JSKN003 IS AN ANTIBODY DUPLICATED DRUG (ADC) TARGETING HER2 CURRENTLY IN CLINICAL TRIALS IN AUSTRALIA AND CHINA, AND ADVANCING A PHASE III CLINICAL TRIAL IN CHINA. Corning Jerry Biopharmaceuticals is a biopharmaceutical company focused on the treatment of tumors with several products in different stages of development.
CORNING JERRY BIOPHARMACEUTICALS (ALPHAMAB ONCOLOGY) ANNOUNCED THE LATEST RESULTS OF A PHASE I CLINICAL TRIAL OF ITS DRUG JSKN003 FOR THE TREATMENT OF HER2-EXPRESSED LATE-STAGE SOLID TUMORS ON APRIL 5-10, 2024. The study showed that JSKN003 had good tolerability and safety in patients with late-stage and metastatic solid tumors, and showed initial antitumor activity. The results include data from 32 patients, most of whom received at least three-line systemic therapy. In terms of efficacy, the objective mitigation rate (ORR) and disease control rate (DCR) are 56.3% and 90.6%, respectively. The drug has a low rate of hematotoxicity and interstitial lung disease (ILD). JSKN003 IS AN ANTIBODY DUPLICATED DRUG (ADC) TARGETING HER2 CURRENTLY IN CLINICAL TRIALS IN AUSTRALIA AND CHINA, AND ADVANCING A PHASE III CLINICAL TRIAL IN CHINA. Corning Jerry Biopharmaceuticals is a biopharmaceutical company focused on the treatment of tumors with several products in different stages of development.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more